Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) will hold its 3Q20 earnings conference call with the financial community on 2nd November 2020 at 8:30 AM Eastern Time.
The conference call will be webcast live on Internet at www.eagleus.com
Earnings Expectation
Eagle Pharmaceuticals, Inc. is reporting third quarter financial results on Monday 2nd November 2020, before market open.
According to analysts surveyed by Thomson Reuters, EGRX is expected to report 3Q20 income of $ 0.28 per share from revenue of $ 47.02 million. For the full year, analysts anticipate top line of $ 193.10 million, while looking forward to income of $ 2.19 per share bottom line.
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkins lymphoma (NHL); and Belrapzo, a chemotherapeutic agent for CLL and Indolent NHL. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke; EP-5101 (PEMFEXY) for lung cancer and mesothelioma; EGL-5385-C-1701 (fulvestrant) for breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock.
